Timothy Pigot - Jan 22, 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role: CHIEF COMMERCIAL OFFICER
Signature: /s/ George A. Eldridge, Attorney-in-Fact
Stock symbol: AVTE
Transactions as of: Jan 22, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/24/2024, 06:00 PM
Previous filing: Mar 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AVTE	Common Stock						1.29K	Jan 22, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVTE	Stock Option (Right to Buy)	Award	$0	+66.6K		$0.00	66.6K	Jan 22, 2024	Common Stock	66.6K	$20.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,291 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
F2	This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.